HK1127486A1 - Therapeutic vaccine - Google Patents

Therapeutic vaccine

Info

Publication number
HK1127486A1
HK1127486A1 HK09105160.4A HK09105160A HK1127486A1 HK 1127486 A1 HK1127486 A1 HK 1127486A1 HK 09105160 A HK09105160 A HK 09105160A HK 1127486 A1 HK1127486 A1 HK 1127486A1
Authority
HK
Hong Kong
Prior art keywords
therapeutic vaccine
vaccine
therapeutic
Prior art date
Application number
HK09105160.4A
Other languages
English (en)
Chinese (zh)
Inventor
Andrea Pfeifer
Claude Nicolau
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37836865&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1127486(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of HK1127486A1 publication Critical patent/HK1127486A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector
HK09105160.4A 2005-12-12 2009-06-09 Therapeutic vaccine HK1127486A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05027091 2005-12-12
EP06009098 2006-05-02
PCT/EP2006/011861 WO2007068411A2 (en) 2005-12-12 2006-12-08 Therapeutic vaccine

Publications (1)

Publication Number Publication Date
HK1127486A1 true HK1127486A1 (en) 2009-09-25

Family

ID=37836865

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09105160.4A HK1127486A1 (en) 2005-12-12 2009-06-09 Therapeutic vaccine

Country Status (24)

Country Link
US (2) US7807175B2 (xx)
EP (2) EP2380588B1 (xx)
JP (2) JP5249043B2 (xx)
KR (2) KR101152557B1 (xx)
CN (1) CN101330923B (xx)
AR (1) AR058327A1 (xx)
AU (1) AU2006326283B2 (xx)
BR (1) BRPI0619747B8 (xx)
CA (1) CA2633399C (xx)
CR (1) CR9994A (xx)
DK (1) DK1959991T3 (xx)
EC (1) ECSP088531A (xx)
ES (2) ES2407429T3 (xx)
HK (1) HK1127486A1 (xx)
IL (1) IL191397A (xx)
MA (1) MA30252B1 (xx)
MY (1) MY181173A (xx)
NO (1) NO346055B1 (xx)
NZ (1) NZ568384A (xx)
RU (2) RU2440824C2 (xx)
SG (1) SG172617A1 (xx)
TW (1) TWI537000B (xx)
WO (1) WO2007068411A2 (xx)
ZA (1) ZA200804918B (xx)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR101439828B1 (ko) 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
EP2102165A2 (en) 2006-11-24 2009-09-23 AC Immune S.A. N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP2106802A1 (en) 2008-04-02 2009-10-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Modified peptides as synthetic vaccines in amyloid-associated disease
KR102469853B1 (ko) 2008-04-11 2022-11-22 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP3936122A1 (en) 2008-11-24 2022-01-12 Massachusetts Institute Of Technology Methods and compositions for localized agent delivery
CA2755683A1 (en) * 2009-03-18 2010-09-23 Ac Immune S.A. Method for therapeutic use
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
KR100929372B1 (ko) * 2009-05-22 2009-12-02 고려대학교 산학협력단 아밀로이드 베타 단편을 유효성분으로 포함하는 돌연변이 ｓｏｄ1에 의한 ａｌｓ 예방 및 치료용 조성물
AT508638B1 (de) * 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
AU2010294214B2 (en) 2009-09-11 2015-05-07 Vivoryon Therapeutics N.V. Heterocylcic derivatives as inhibitors of glutaminyl cyclase
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US20110229556A1 (en) * 2010-03-19 2011-09-22 Massachusetts Institute Of Technology Lipid-coated polymer particles for immune stimulation
BR112012023501A2 (pt) 2010-03-19 2016-05-31 Massachusetts Inst Technology vesículas lipídicas multilamelares, composição farmacêutica e método
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
CN102939282B (zh) 2010-04-16 2015-12-02 Ac免疫有限公司 用于治疗与淀粉状蛋白或淀粉状蛋白样蛋白有关的疾病的化合物
EP2377860A1 (en) 2010-04-16 2011-10-19 AC Immune S.A. Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
TW201223561A (en) 2010-10-26 2012-06-16 Ac Immune Sa Preparation of an antigenic construct
AU2011337704B2 (en) 2010-11-30 2017-06-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2012078968A2 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
KR20160099732A (ko) * 2011-09-23 2016-08-22 에이씨 이뮨 에스.에이. 백신 요법
MX356800B (es) 2012-04-05 2018-06-13 Ac Immune Sa Anticuerpo tau humanizado.
MX2015012872A (es) 2013-03-15 2016-02-03 Ac Immune Sa Anticuerpos anti-tau y metodos de uso.
ES2904276T3 (es) 2013-09-27 2022-04-04 Massachusetts Inst Technology Nanoestructuras de proteínas biológicamente activas sin vehículo
US10654807B2 (en) * 2013-12-20 2020-05-19 The University Of Kansas Toll-like receptor 8 agonists
RU2746356C2 (ru) 2014-12-19 2021-04-12 Чугаи Сейяку Кабусики Кайся Антитела к с5 и способы их применения
JP6887685B2 (ja) 2015-08-12 2021-06-16 マサチューセッツ インスティテュート オブ テクノロジー ナノ粒子の細胞表面共役
JP7185530B2 (ja) 2016-06-13 2022-12-07 トルク セラピューティクス， インコーポレイテッド 免疫細胞機能を促進するための方法および組成物
CN116251182A (zh) 2016-08-05 2023-06-13 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
WO2018081085A1 (en) * 2016-10-25 2018-05-03 The Regents Of The University Of California Methods of diagnosis and treatment of alzheimer's disease
WO2018204302A1 (en) 2017-05-01 2018-11-08 Vanderbilt University Phosphorylated hexaacyl disaccharides (phads) for treating or preventing infections
CN111432836A (zh) 2017-09-05 2020-07-17 转矩医疗股份有限公司 治疗性蛋白质组合物及其制备和使用方法
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
AU2018355325A1 (en) 2017-10-25 2020-05-07 Ac Immune S.A. Compositions of phosphorylated tau peptides and uses thereof
CN108037277A (zh) * 2017-12-07 2018-05-15 中国兽医药品监察所 一种区分牛布鲁氏菌疫苗免疫与自然感染状态的方法
CN112165956A (zh) * 2018-04-10 2021-01-01 Ac免疫有限公司 抗Aβ治疗性疫苗
JP2021521149A (ja) * 2018-04-10 2021-08-26 エイシー イミューン ソシエテ アノニム 抗−ａベータ治療用ワクチン
CN113710269A (zh) 2019-02-08 2021-11-26 Ac免疫有限公司 磷酸化Tau肽疫苗的安全施用方法
JP2022529529A (ja) 2019-04-24 2022-06-22 ヤンセン ファーマシューティカルズ，インコーポレーテッド タウワクチンの異種投与
AU2020277682A1 (en) 2019-05-21 2021-12-23 Ac Immune Sa Anti-Abeta vaccine therapy
WO2021207303A1 (en) * 2020-04-07 2021-10-14 Alsatech, Inc. Immune stimulation against coronavirus infections

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847082A (en) 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
NZ540564A (en) * 1999-11-29 2007-04-27 Neurochem Int Ltd Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases
DE10003992A1 (de) * 2000-01-29 2001-08-09 Bosch Gmbh Robert Sensoranordnung
JP5153986B2 (ja) * 2000-09-06 2013-02-27 アベンティス・ファーマ・ソシエテ・アノニム アミロイドーシスと関連する疾患のための方法及び組成物
EP1203614A1 (de) 2000-11-03 2002-05-08 Polymun Scientific Immunbiologische Forschung GmbH Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
CA2488230C (en) * 2002-04-29 2013-04-09 Yves Claude Nicolau Inositol pyrophosphates, and methods of use thereof
JP2006525226A (ja) 2002-12-24 2006-11-09 ニューロケム （インターナショナル） リミテッド β−アミロイド関連疾患の治療のための治療用製剤
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
DE602004020334D1 (de) * 2003-06-02 2009-05-14 Varleigh Ltd Komplementinhibitoren aus zecken
WO2005012330A2 (en) * 2003-07-30 2005-02-10 Brigham And Women's Hospital, Inc. AMYLOID β-PEPTIDE AND METHODS OF USE
PE20061401A1 (es) * 2004-12-15 2006-12-23 Neuralab Ltd ANTICUERPOS Aß PARA MEJORAR LA COGNICION
EP1676859A1 (en) * 2004-12-30 2006-07-05 Pevion Biotech Ltd. Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide
RU2015111675A (ru) * 2005-12-12 2015-08-10 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами

Also Published As

Publication number Publication date
IL191397A (en) 2016-05-31
NO346055B1 (no) 2022-01-24
EP2380588B1 (en) 2015-08-05
NZ568384A (en) 2011-09-30
MY181173A (en) 2020-12-21
AR058327A1 (es) 2008-01-30
CA2633399A1 (en) 2007-06-21
RU2011141308A (ru) 2013-04-20
CN101330923B (zh) 2015-01-07
US20080267986A1 (en) 2008-10-30
JP5249043B2 (ja) 2013-07-31
DK1959991T3 (da) 2013-06-17
RU2008128133A (ru) 2010-01-20
US7807175B2 (en) 2010-10-05
ES2551604T3 (es) 2015-11-20
CA2633399C (en) 2016-01-26
ZA200804918B (en) 2011-10-26
SG172617A1 (en) 2011-07-28
US8603487B2 (en) 2013-12-10
EP1959991A2 (en) 2008-08-27
EP1959991B1 (en) 2013-03-20
JP2013126993A (ja) 2013-06-27
KR101152557B1 (ko) 2012-09-07
AU2006326283A1 (en) 2007-06-21
KR20080084830A (ko) 2008-09-19
BRPI0619747B8 (pt) 2021-05-25
AU2006326283B2 (en) 2012-01-19
MA30252B1 (fr) 2009-03-02
WO2007068411A3 (en) 2007-08-23
ECSP088531A (es) 2008-07-30
RU2440824C2 (ru) 2012-01-27
BRPI0619747B1 (pt) 2019-03-26
CR9994A (es) 2008-09-22
ES2407429T3 (es) 2013-06-12
KR20120061049A (ko) 2012-06-12
BRPI0619747A2 (pt) 2011-10-18
EP2380588A1 (en) 2011-10-26
JP2009519915A (ja) 2009-05-21
TWI537000B (zh) 2016-06-11
WO2007068411A2 (en) 2007-06-21
CN101330923A (zh) 2008-12-24
TW200744630A (en) 2007-12-16
NO20082216L (no) 2008-08-22
KR101236611B1 (ko) 2013-03-04
US20090238840A1 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
ZA200804918B (en) Therapeutic vaccine
TWI365191B (en) Vaccine
IL192084A0 (en) Vaccine
GB0504436D0 (en) Vaccine
GB0522765D0 (en) Combination vaccine manufacture
GB0409940D0 (en) Vaccine
GB0411150D0 (en) Vaccine
GB0507003D0 (en) Therapeutic
GB0515135D0 (en) Vaccine
GB0518720D0 (en) Therapeutic combination
ZA200709207B (en) Vaccine
GB0501655D0 (en) Therapeutic use
GB0516944D0 (en) Vaccine
GB0413510D0 (en) Vaccine
GB0810662D0 (en) Vaccine
ZA200709210B (en) Vaccine
GB0428381D0 (en) Vaccine
GB0412407D0 (en) Vaccine
GB0526412D0 (en) Vaccine
GB0406598D0 (en) Vaccine
GB0419918D0 (en) Vaccine
GB0521164D0 (en) Vaccine
GB0523445D0 (en) Vaccine
IL186591A0 (en) Vaccine
GB0503000D0 (en) Anti-atheroma vaccine